Get the Stockscreener App
1.39
23.01%
0.26
Rein Therapeutics Inc stock is traded at $1.39, with a volume of 224.84K.
It is up +23.01% in the last 24 hours and up +11.20% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
See More
Previous Close:
$1.13
Open:
$1.22
24h Volume:
224.84K
Relative Volume:
4.90
Market Cap:
$32.39M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+9.45%
1M Performance:
+11.20%
6M Performance:
-32.85%
1Y Performance:
+0.00%
1-Day Range:
$1.15
$1.40
1-Week Range:
$1.06
$1.40
52-Week Range:
$1.04
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.39 | 26.04M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Risk vs reward if holding onto Rein Therapeutics Inc.Weekly Trade Analysis & Verified Momentum Watchlists - Newser
Analyzing net buyer seller activity in Rein Therapeutics Inc.Index Update & Weekly High Return Stock Forecasts - Newser
Real time alert setup for Rein Therapeutics Inc. performanceWeekly Investment Report & Community Trade Idea Sharing - Newser
Will a bounce in Rein Therapeutics Inc. offer an exitDividend Hike & Free High Return Stock Watch Alerts - Newser
Is Rein Therapeutics Inc. stock reversal real or fakePrice Action & Growth Focused Investment Plans - Newser
Real time breakdown of Rein Therapeutics Inc. stock performanceAnalyst Downgrade & Entry and Exit Point Strategies - Newser
Can Rein Therapeutics Inc. rally from current levels2025 Pullback Review & Free Weekly Chart Analysis and Trade Guides - Newser
Rein Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Momentum & Technical Pattern Based Signals - Newser
Market reaction to Rein Therapeutics Inc.’s recent news2025 Sector Review & Short-Term High Return Strategies - Newser
How to interpret RSI for Rein Therapeutics Inc. stockWeekly Gains Summary & Smart Money Movement Alerts - Newser
Rein Therapeutics Inc. Moves Into Bullish Territory Based on MACD getLinesFromResByArray error: size == 0 - sisain.net
Smart tools for monitoring Rein Therapeutics Inc.’s price actionJuly 2025 Intraday Action & Daily Stock Trend Reports - Newser
How to integrate Rein Therapeutics Inc. into portfolio analysis toolsPortfolio Performance Report & Weekly Breakout Stock Alerts - Newser
What to expect from Rein Therapeutics Inc. in the next 30 days2025 Key Lessons & Safe Capital Allocation Plans - Newser
Risk adjusted return profile for Rein Therapeutics Inc. analyzedJuly 2025 Retail & Daily Stock Trend Reports - Newser
Short interest data insights for Rein Therapeutics Inc.2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
Published on: 2025-08-30 22:34:22 - Newser
Applying Wyckoff theory to Rein Therapeutics Inc. stockWeekly Profit Analysis & Real-Time Sentiment Analysis - Newser
What machine learning models say about Rein Therapeutics Inc.Watch List & Momentum Based Trading Ideas - Newser
How cyclical is Rein Therapeutics Inc.’s revenue stream getLinesFromResByArray error: size == 0 - sisain.net
Rein Therapeutics Inc. Hits Price Floor — Bounce Incoming getLinesFromResByArray error: size == 0 - sisain.net
Top chart patterns to watch in Rein Therapeutics Inc.July 2025 Institutional & Stepwise Swing Trade Plans - Newser
What the charts say about Rein Therapeutics Inc. todayWeekly Trade Recap & High Accuracy Investment Entry Signals - Newser
Can Rein Therapeutics Inc. grow without external funding2025 Winners & Losers & Free Technical Pattern Based Buy Signals - sundaytimes.kr
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):